The Indianapolis-based pharmaceutical company announced plans for four new manufacturing sites, but has not decided where they will go.

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Megan Tjelle, a young woman from Chicago, lost an additional 50 pounds with the help of the medication Wegovy. Her story is a ...

Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.

Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...